The MPTP neurotoxic lesion model of Parkinson's disease activates the apolipoprotein E cascade in the mouse brain

Experimental Neurology

Volumn 233, Issue 1, 2012, Pages 513-522

  Domenger, D ^a   Dea, D ^a   Theroux, L ^a   Moquin, L ^a   Gratton, A ^a   Poirier, J ^a,b  

^a DOUGLAS MENTAL HEALTH UNIVERSITY INSTITUTE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Apolipoprotein E; Compensatory mechanisms; Dopamine; GFAP; LDLR; LRP; Mouse model; MPTP; Parkinson's disease; Reinnervation

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; APOLIPOPROTEIN E; BRAIN MONOAMINE; CELL MARKER; DOPAMINE; GLIAL FIBRILLARY ACIDIC PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MESSENGER RNA; SYNAPTOPHYSIN; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOLIPOPROTEIN E GENE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DEAFFERENTATION; DISEASE ASSOCIATION; DOPAMINE METABOLISM; GENE; GENE EXPRESSION REGULATION; GLIAL FIBRILLARY ACIDIC PROTEIN GENE; HIPPOCAMPUS; IMMUNOASSAY; LOW DENSITY LIPOPROTEIN RECEPTOR GENE; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN GENE; MALE; MOUSE; NERVE CELL PLASTICITY; NERVE REGENERATION; NEUROCHEMISTRY; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RECEPTOR GENE; REINNERVATION; TISSUE DIFFERENTIATION; UPREGULATION;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANALYSIS OF VARIANCE; ANIMALS; APOLIPOPROTEINS E; BIOGENIC MONOAMINES; BRAIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISEASE MODELS, ANIMAL; ELECTROCHEMICAL TECHNIQUES; GENE EXPRESSION REGULATION; GLIAL FIBRILLARY ACIDIC PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-1; MALE; MICE; MICE, INBRED C57BL; MPTP POISONING; NEUROTOXINS; RECEPTORS, LDL; RNA, MESSENGER; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 84856232956     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2011.11.031     Document Type: Article

References (68)

1. Anglade P., Tsuji S., Javoy-Agid F., Agid Y., Hirsch E.C. Plasticity of nerve afferents to nigrostriatal neurons in Parkinson's disease. Ann. Neurol. 1995, 37:265-272.
2. Arendt T., Schindler C., Brückner M.K., Eschrich K., Bigl V., Zedlick D., Marcova L. Plastic neuronal remodeling is impaired in patients with Alzheimer's disease carrying apolipoprotein epsilon 4 allele. J. Neurosci. 1997, 17:516-529.
3. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J. Neurol. Sci. 1973, 20:415-455.
4. Bezard E., Dovero S., Imbert C., Boraud T., Gross C.E. Spontaneous long-term compensatory dopaminergic sprouting in MPTP-treated mice. Synapse 2000, 38:363-368.
5. Blanchard V., Anglade P., Dziewczapolski G., Savasta M., Agid Y., Raisman-Vozari R. Dopaminergic sprouting in the rat striatum after partial lesion of the substantia nigra. Brain Res. 1996, 709:319-325.
6. Borta A., Höglinger G.U. Dopamine and adult neurogenesis. J. Neurochem. 2007, 100:587-595.
7. Boyles J.K., Pitas R.E., Wilson E., Mahley R.W., Taylor J.M. Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system. J. Clin. Invest. 1985, 76:1501-1513.
8. Boyles J.K., Zoellner C.D., Anderson L.J., Kosik L.M., Pitas R.E., Weisgraber K.H., Hui D.Y., Mahley R.W., Gebicke-Haerter P.J., Ignatius M.J. A role for apolipoprotein E, apolipoprotein A-I, and low density lipoprotein receptors in cholesterol transport during regeneration and remyelination of the rat sciatic nerve. J. Clin. Invest. 1989, 83:1015-1031.
9. DeMattos R.B., Rudel L.L., Williams D.L. Biochemical analysis of cell-derived apoE3 particles active in stimulating neurite outgrowth. J. Lipid Res. 2001, 42:976-987.
10. Ehringer H., Hornykiewicz O. Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system. Klin. Wochenschr. 1960, 38:1236-1239.
11. Fagan A.M., Bu G., Sun Y., Daugherty A., Holtzman D.M. Apolipoprotein E-containing high density lipoprotein promotes neurite outgrowth and is a ligand for the low density lipoprotein receptor-related protein. J. Biol. Chem. 1996, 271:30121-30125.
12. Finkelstein D.I., Stanic D., Parish C.L., Tomas D., Dickson K., Horne M.K. Axonal sprouting following lesions of the rat substantia nigra. Neuroscience 2000, 97:99-112.
13. Francis J.W., Von Visger J., Markelonis G.J., Oh T.H. Neuroglial responses to the dopaminergic neurotoxicant 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mouse striatum. Neurotoxicol. Teratol. 1995, 17:7-12.
14. Fryer J.D., Demattos R.B., McCormick L.M., O'Dell M.A., Spinner M.L., Bales K.R., Paul S.M., Sullivan P.M., Parsadanian M., Bu G., Holtzman D.M. The low density lipoprotein receptor regulates the level of central nervous system human and murine apolipoprotein E but does not modify amyloid plaque pathology in PDAPP mice. J. Biol. Chem. 2005, 280:25754-25759.
15. Gallardo G., Schlüter O.M., Südhof T.C. A molecular pathway of neurodegeneration linking alpha-synuclein to ApoE and Abeta peptides. Nat. Neurosci. 2008, 11:301-308.
16. Handelmann G.E., Boyles J.K., Weisgraber K.H., Mahley R.W., Pitas R.E. Effects of apolipoprotein E, beta-very low density lipoproteins, and cholesterol on the extension of neurites by rabbit dorsal root ganglion neurons in vitro. J. Lipid Res. 1992, 33:1677-1688.
17. Hefti F., Enz A., Melamed E. Partial lesions of the nigrostriatal pathway in the rat. Acceleration of transmitter synthesis and release of surviving dopaminergic neurones by drugs. Neuropharmacology 1985, 24:19-23.
18. Heikkila R.E., Hess A., Duvoisin R.C. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. Science 1984, 224:1451-1453.
19. Hirsch E.C., Duyckaerts C., Javoy-Agid F., Hauw J.J., Agid Y. Does adrenal graft enhance recovery of dopaminergic neurons in Parkinson's disease?. Ann. Neurol. 1990, 27:676-682.
20. Holtzman D.M., Pitas R.E., Kilbridge J., Nathan B., Mahley R.W., Bu G., Schwartz A.L. Low density lipoprotein receptor-related protein mediates apolipoprotein E-dependent neurite outgrowth in a central nervous system-derived neuronal cell line. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:9480-9484.
21. Huang X., Chen P.C., Poole C. APOE-[epsilon]2 allele associated with higher prevalence of sporadic Parkinson disease. Neurology 2004, 62:2198-2202.
22. Huang X., Chen P., Kaufer D.I., Tröster A.I., Poole C. Apolipoprotein E and dementia in Parkinson disease: a meta-analysis. Arch. Neurol. 2006, 63:189-193.
23. Ignatius M.J., Gebicke-Härter P.J., Skene J.H., Schilling J.W., Weisgraber K.H., Mahley R.W., Shooter E.M. Expression of apolipoprotein E during nerve degeneration and regeneration. Proc. Natl. Acad. Sci. U. S. A. 1986, 83:1125-1129.
24. Iwata A., Browne K.D., Chen X.-H., Yuguchi T., Smith D.H. Traumatic brain injury induces biphasic upregulation of ApoE and ApoJ protein in rats. J. Neurosci. Res. 2005, 82:103-114.
25. Javitch J.A., D'Amato R.J., Strittmatter S.M., Snyder S.H. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc. Natl. Acad. Sci. U. S. A. 1985, 82:2173-2177.
26. Jellinger K.A. Striatal beta-amyloid deposition in Parkinson disease with dementia. J. Neuropathol. Exp. Neurol. 2008, 67:484. author reply 484-485.
27. Jellinger K.A., Seppi K., Wenning G.K., Poewe W. Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease. J. Neural Transm. 2002, 109:329-339.
28. Koller W.C., Glatt S.L., Hubble J.P., Paolo A., Tröster A.I., Handler M.S., Horvat R.T., Martin C., Schmidt K., Karst A. Apolipoprotein E genotypes in Parkinson's disease with and without dementia. Ann. Neurol. 1995, 37:242-245.
29. Koob A.O., Paulino A.D., Masliah E. GFAP reactivity, apolipoprotein E redistribution and cholesterol reduction in human astrocytes treated with alpha-synuclein. Neurosci. Lett. 2010, 469:11-14.
30. LaDu M.J., Shah J.A., Reardon C.A., Getz G.S., Bu G., Hu J., Guo L., Van Eldik L.J. Apolipoprotein E and apolipoprotein E receptors modulate A beta-induced glial neuroinflammatory responses. Neurochem. Int. 2001, 39:427-434.
31. Langston J.W., Ballard P., Tetrud J.W., Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983, 219:979-980.
32. Leduc V., Domenger D., De Beaumont L., Lalonde D., Bélanger-Jasmin S., Poirier J. Function and comorbidities of apolipoprotein e in Alzheimer's disease. Int. J. Alzheimers Dis. 2011, 2011:974361.
33. Lewis P.D. Parkinsonism-neuropathology. Br. Med. J. 1971, 3:690-692.
34. Li Y.J., Hauser M.A., Scott W.K., Martin E.R., Booze M.W., Qin X.J., Walter J.W., Nance M.A., Hubble J.P., Koller W.C., Pahwa R., Stern M.B., Hiner B.C., Jankovic J., Goetz C.G., Small G.W., Mastaglia F., Haines J.L., Pericak-Vance M.A., Vance J.M. Apolipoprotein E controls the risk and age at onset of Parkinson disease. Neurology 2004, 62:2005-2009.
35. Liu Q., Zerbinatti C.V., Zhang J., Hoe H.-S., Wang B., Cole S.L., Herz J., Muglia L., Bu G. Amyloid precursor protein regulates brain apolipoprotein E and cholesterol metabolism through lipoprotein receptor LRP1. Neuron 2007, 56:66-78.
36. Liu Q., Trotter J., Zhang J., Peters M.M., Cheng H., Bao J., Han X., Weeber E.J., Bu G. Neuronal LRP1 knockout in adult mice leads to impaired brain lipid metabolism and progressive, age-dependent synapse loss and neurodegeneration. J. Neurosci. 2010, 30:17068-17078.
37. Lloyd K.G., Davidson L., Hornykiewicz O. The neurochemistry of Parkinson's disease: effect of L-dopa therapy. J. Pharmacol. Exp. Ther. 1975, 195:453-464.
38. Mahley R.W. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988, 240:622-630.
39. Mahley R.W., Weisgraber K.H., Huang Y. Apolipoprotein E4: A causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:5644-5651.
40. Masliah E., Mallory M., Veinbergs I., Miller A., Samuel W. Alterations in apolipoprotein E expression during aging and neurodegeneration. Prog. Neurobiol. 1996, 50:493-503.
41. Mounayar S., Boulet S., Tandé D., Jan C., Pessiglione M., Hirsch E.C., Féger J., Savasta M., François C., Tremblay L. A new model to study compensatory mechanisms in MPTP-treated monkeys exhibiting recovery. Brain 2007, 130:2898-2914.
42. Mukaetova-Ladinska E.B., Hurt J., Jakes R., Xuereb J., Honer W.G., Wischik C.M. Alpha-synuclein inclusions in Alzheimer and Lewy body diseases. J. Neuropathol. Exp. Neurol. 2000, 59:408-417.
43. Mulder M., Jansen P.J., Janssen B.J.A., van de Berg W.D.J., van der Boom H., Havekes L.M., de Kloet R.E., Ramaekers F.C.S., Blokland A. Low-density lipoprotein receptor-knockout mice display impaired spatial memory associated with a decreased synaptic density in the hippocampus. Neurobiol. Dis. 2004, 16:212-219.
44. Nathan B.P., Bellosta S., Sanan D.A., Weisgraber K.H., Mahley R.W., Pitas R.E. Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. Science 1994, 264:850-852.
45. Page K.J., Hollister R.D., Hyman B.T. Dissociation of apolipoprotein and apolipoprotein receptor response to lesion in the rat brain: an in situ hybridization study. Neuroscience 1998, 85:1161-1171.
46. Park J.-H., Enikolopov G. Transient elevation of adult hippocampal neurogenesis after dopamine depletion. Exp. Neurol. 2010, 222:267-276.
47. Paulus W., Jellinger K. The neuropathologic basis of different clinical subgroups of Parkinson's disease. J. Neuropathol. Exp. Neurol. 1991, 50:743-755.
48. Petzinger G.M., Fisher B., Hogg E., Abernathy A., Arevalo P., Nixon K., Jakowec M.W. Behavioral motor recovery in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned squirrel monkey (Saimiri sciureus): changes in striatal dopamine and expression of tyrosine hydroxylase and dopamine transporter proteins. J. Neurosci. Res. 2006, 83:332-347.
49. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001, 29:e45.
50. Pileblad E., Carlsson A. Studies on the acute and long-term changes in dopamine and noradrenaline metabolism in mouse brain following administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Pharmacol. Toxicol. 1988, 62:213-222.
51. Poirier J. Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease. Trends Neurosci. 1994, 17:525-530.
52. Poirier J. Apolipoprotein E and Alzheimer's disease. A role in amyloid catabolism. Ann. N. Y. Acad. Sci. 2000, 924:81-90.
53. Poirier J., Hess M., May P.C., Finch C.E. Astrocytic apolipoprotein E mRNA and GFAP mRNA in hippocampus after entorhinal cortex lesioning. Brain Res. Mol. Brain Res. 1991, 11:97-106.
54. Poirier J., Davignon J., Bouthillier D., Kogan S., Bertrand P., Gauthier S. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet 1993, 342:697-699.
55. Poirier J.K., Baccichet A., Dea D., Gauthier S. Cholesterol synthesis and lipoprotein reuptake during synaptic remodelling in hippocampus in adult rats. Neuroscience 1993, 55:81-90.
56. Przedborski S., Vila M. MPTP: a review of its mechanisms of neurotoxicity. Clin. Neurosci. Res. 2001, 1:407-418.
57. Reinhard J.F., Diliberto E.J., Viveros O.H., Daniels A.J. Subcellular Compartmentalization of 1-methyl-4-phenylpyridinium with Catecholamines in Adrenal Medullary Chromaffin Vesicles May Explain the Lack of Toxicity to Adrenal Chromaffin Cells. Proc. Natl. Acad. Sci. U. S. A. 1987, 84:8160-8164.
58. Saunders A.M., Strittmatter W.J., Schmechel D., George-Hyslop P.H., Pericak-Vance M.A., Joo S.H., Rosi B.L., Gusella J.F., Crapper-MacLachlan D.R., Alberts M.J. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993, 43:1467-1472.
59. Steward O., Torre E.R., Phillips L.L., Trimmer P.A. The process of reinnervation in the dentate gyrus of adult rats: time course of increases in mRNA for glial fibrillary acidic protein. J. Neurosci. 1990, 10:2373-2384.
60. Steward O., Kelley M.S., Torre E.R. The process of reinnervation in the dentate gyrus of adult rats: temporal relationship between changes in the levels of glial fibrillary acidic protein (GFAP) and GFAP mRNA in reactive astrocytes. Exp. Neurol. 1993, 124:167-183.
61. Strömberg I., Björklund H., Dahl D., Jonsson G., Sundström E., Olson L. Astrocyte responses to dopaminergic denervations by 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine as evidenced by glial fibrillary acidic protein immunohistochemistry. Brain Res. Bull. 1986, 17:225-236.
62. Sundström E., Samuelsson E.B. Comparison of key steps in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in rodents. Pharmacol. Toxicol. 1997, 81:226-231.
63. Sundström E., Strömberg I., Tsutsumi T., Olson L., Jonsson G. Studies on the effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in C57BL/6 mice. Comparison with three other strains of mice. Brain Res. 1987, 405:26-38.
64. Wallace R.A., Boldry R., Schmittgen T., Miller D., Uretsky N. Effect of 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine (MPTP) on monoamine neurotransmitters in mouse brain & heart. Life Sci. 1984, 35:285-291.
65. White F., Nicoll J.A., Horsburgh K. Alterations in ApoE and ApoJ in relation to degeneration and regeneration in a mouse model of entorhinal cortex lesion. Exp. Neurol. 2001, 169:307-318.
66. Wu D.-C., Teismann P., Tieu K., Vila M., Jackson-Lewis V., Ischiropoulos H., Przedborski S. NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:6145-6150.
67. Zigmond M.J., Acheson A.L., Stachowiak M.K., Stricker E.M. Neurochemical compensation after nigrostriatal bundle injury in an animal model of preclinical parkinsonism. Arch. Neurol. 1984, 41:856-861.
68. Zigmond R.E., Schwarzschild M.A., Rittenhouse A.R. Acute regulation of tyrosine hydroxylase by nerve activity and by neurotransmitters via phosphorylation. Annu. Rev. Neurosci. 1989, 12:415-461.